Cinnaron

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinnaron

What is Cinnaron?

Cinnaron is a pharmaceutical formulation containing cinnarizine, a medication belonging to the class of antihistamines and calcium channel blockers. It is primarily used to manage symptoms associated with balance disorders and motion sickness.

Mechanism of Action

Cinnaron works by interfering with the transmission of signals between the vestibular apparatus of the inner ear and the vomiting center in the brain. It inhibits the stimulation of the labyrinth, which helps to reduce sensations of spinning or motion. Additionally, cinnarizine acts as a calcium antagonist, preventing the constriction of blood vessels and improving microcirculation in the inner ear.

Primary Uses

Cinnaron is typically used for the management of various vestibular and circulatory conditions, including:

  • Vestibular Disorders: It helps alleviate symptoms of vertigo, tinnitus (ringing in the ears), nausea, and vomiting associated with Meniere's disease and other inner ear disturbances.
  • Motion Sickness: It is used to prevent and treat symptoms of travel-related sickness, such as dizziness and nausea occurring during movement in cars, boats, or airplanes.
  • Vascular Symptoms: Due to its effect on blood flow, it may be used to address symptoms resulting from peripheral circulatory disorders.

Regulatory References

  1. NIH, National Library of Medicine

What side effects are possible with Cinnaron?

Possible side effects and safety information

The official safety documentation for Cinnarizine (Cinnaron) classifies potential adverse effects based on frequency and the affected body system, consistent with regulatory standards.

Officially Documented Adverse Reactions by Frequency

Reactions classified as common (occurring in 1% to less than 10% of patients) primarily affect the nervous and gastrointestinal systems. These include Somnolence (drowsiness), Nausea, and Weight Increased. Less frequent reactions are classified as uncommon (e.g., Vomiting and Upper Abdominal Pain).

Reactions of not known frequency, generally derived from post-marketing reports, include movement-related effects such as Extrapyramidal Disorder and Parkinsonism. Other documented reactions include Hypersensitivity, Cholestatic Jaundice (a hepatobiliary disorder), and serious skin reactions such as Subacute Cutaneous Lupus Erythematosus (SCLE).

Safety Considerations and Exposure Patterns

The regulatory safety profile highlights specific risk factors related to treatment duration and patient characteristics. Somnolence is noted as being more likely to appear at the start of treatment, while Extrapyramidal Symptoms are associated with long-term use and pose a particular safety consideration for older adults.

Official labeling advises caution for patients with hepatic or renal insufficiency and specifically notes that use may aggravate Parkinson's disease. The medicine is advised against in cases of known hypersensitivity or in patients with porphyria.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented overdose profile of Cinnaron (Cinnarizine) as stated in government regulatory documents.

Documented Overdose Manifestations

Acute Cinnarizine overdoses have been reported across a dose range of 90 to 2,250 mg. The most common clinical signs are attributed to the drug’s anticholinergic activity and include alterations in consciousness (from somnolence to stupor and coma), vomiting, hypotonia (decreased muscle tone), and extrapyramidal symptoms (movement disorders).

Feature Regulatory Documentation Summary
Severe Outcomes Deaths have been reported following single and polydrug overdoses. Seizures developed in a small number of young children [Source 1.4, 1.9, 2.1].
Treatment Focus No specific antidote is known. Treatment is symptomatic and supportive care [Source 1.4, 1.9, 2.1, 2.2].

When Urgent Medical Help is Required

Upon suspected overdose, urgent medical attention must be sought immediately to manage the documented severe neurological and systemic manifestations. Treatment focuses on supportive measures and may include consideration of administering activated charcoal if the patient presents within one hour of a potentially toxic ingestion. Regulatory documentation advises making contact with a poison control centre.

Overdose Profile Summary

Regulatory documents define the overdose profile by outlining the expected neurological manifestations and the most serious documented risks, which include fatalities and seizures in children. Since treatment is limited to supportive care, the official guidance necessitates prompt professional medical intervention to manage the life-threatening CNS effects described in the labeling.

Therapeutic Uses of Cinnaron

Main Uses of Cinnaron

Cinnaron contains cinnarizine, a compound classified as an antihistamine and calcium channel antagonist. It is primarily used to manage symptoms related to balance disorders and peripheral circulatory issues. The medication works by reducing the excitability of the vestibular system in the inner ear and improving blood flow in smaller blood vessels.

Vestibular and Balance Disorders

The primary application of Cinnaron is the treatment of symptoms originating from the inner ear or the vestibular system, which controls balance. It is commonly used for:

  • Vertigo: Managing sensations of spinning or dizziness.
  • Tinnitus: Reducing the perception of ringing or buzzing in the ears.
  • Nystagmus: Addressing involuntary eye movements associated with balance issues.
  • Meniere's Disease: Relieving the cluster of symptoms associated with this inner ear condition, including nausea and vomiting.

Motion Sickness

Cinnaron is used to prevent and treat motion sickness. It helps control the physical responses to motion, such as nausea, vomiting, and cold sweats, by desensitizing the sensory organs responsible for detecting movement.

Peripheral Circulatory Disorders

In addition to its effects on balance, Cinnaron is utilized to improve circulation in the extremities. It acts on the smooth muscles of the blood vessels to promote better blood flow. This application is relevant for conditions such as:

  • Raynaud's Phenomenon: Managing coldness and discoloration in the fingers and toes.
  • Intermittent Claudication: Addressing cramping or pain in the legs caused by poor circulation during physical activity.
  • Acrocyanosis: Reducing persistent blue or cyanotic discoloration of the hands and feet.

Cognitive and Cerebral Symptoms

Due to its ability to improve cerebral blood flow, the medication may be used to address symptoms resulting from poor circulation in the brain. This includes managing difficulties with concentration, memory loss, and irritability in older populations or those with documented vascular issues.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

The eligibility profile for Cinnaron (cinnarizine) is determined by absolute exclusions, specific comorbidities, and age-related limitations, as defined in official regulatory documents.

Classification Population or Condition
Contraindicated (Must Not Use) Patients with known hypersensitivity to cinnarizine or its excipients. Patients with porphyria (an inherited blood condition).
Not Recommended/Use Avoided Children under 5 years of age.
Nursing mothers (lactation): Use is not recommended due to a lack of data on excretion into breast milk.
Conditional Use (Caution Required) Parkinson's disease: Use is only permitted if the potential advantages outweigh the risk of aggravating the condition.

Patients with hepatic or renal insufficiency should use the medicine with care. Older adults require particular caution due to increased susceptibility to adverse effects. | | Safety Not Established | Human Pregnancy: Safety has not been established. Use is generally not advisable in pregnancy. |

This structure reflects the mandated eligibility constraints: absolute prohibition for contraindications, strict restrictions for specific comorbidities, and official non-eligibility for populations lacking sufficient safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents highlight that Cinnaron's interaction profile is primarily defined by pharmacodynamic reinforcement and specific administration constraints.


Documented Pharmacodynamic Interactions

The co-administration of Cinnaron with substances that also cause central nervous system (CNS) depression may lead to an additive or potentiated sedative effect.

Interacting Substance/Class Official Interaction Statement
CNS Depressants Co-use may potentiate the sedative effects of Cinnaron or the co-administered drug.
Tricyclic Antidepressants Specifically noted for the potential to potentiate sedative effects.
Alcohol Officially advised to avoid, as it may potentiate the sedative effects and increase drowsiness.
Ototoxic Drugs May mask the warning signs of ototoxicity (e.g., from aminoglycoside antibiotics).

Administration Constraints and Procedural Interactions

Certain official restrictions are tied to the timing of administration or procedural interference:

  • Dermal Reactivity Indicators (Skin Tests): Cinnaron must be discontinued four days prior to testing, as its antihistamine properties may prevent a positive reaction.
  • Food: The tablets should be taken after meals to diminish the risk of gastric irritation.

Population-Specific Restrictions

  • Parkinson’s Disease: The use of Cinnaron is restricted and should only be administered if the documented advantages strictly outweigh the possible risk of aggravating the underlying condition.

Mechanism of Action

How Cinnaron Works

Cinnaron operates by exerting a targeted effect on key regulatory systems to modulate activity within specific physiological pathways. Its mechanism is defined by a sequence of molecular events that result in physiological adjustments.

Modulation of Primary Receptor Signaling

Cinnaron's primary action involves acting on a defined biological target—the RX receptor system—which is central to specific neural and humoral signaling. The drug acts as a selective modulator to dampen excessive signaling by altering the receptor's activity, resulting in a change in the level of transmitter or mediator signaling within the affected systems.

Interference with Downstream Molecular Cascades

Following receptor engagement, Cinnaron's mechanism involves modifying key steps within the downstream molecular cascade. This action is relevant in contexts involving heightened pathway activation, where the drug suppresses or limits the amplification of signals. By engaging mechanisms that influence feedback regulation, Cinnaron ensures a targeted pathway interference to influence systemic physiological effects.

Modulating Systemic Activity Patterns

The resulting mechanistic cascade influences activity patterns within physiological responses driven by altered signaling patterns. This action results in altered activity leading to a change in the pathway state within the targeted pathways, limiting the overall consequence of excessive mediator activity and modulating the activity of processes within the central or peripheral systems.

Dosage and Administration Information

General Principles of Cinnaron Administration

Cinnaron, which contains the active ingredient Cinnarizine, is intended strictly for oral administration in the form of tablets or capsules. Use is patterned to address two primary clinical scenarios: ongoing maintenance for inner ear conditions and scheduled use for prevention. The medication should be taken after meals to help minimize potential gastric irritation.

Labeled Dosing Regimens

For conditions requiring continuous management, such as balance disorders, the standard adult regimen is typically 25 mg administered three times daily, or 75 mg taken once daily. The maximum daily dosage across all uses must not exceed 225 mg.

For prophylaxis of motion sickness, the administration follows an intermittent schedule. Adults are instructed to take the initial dose (25 mg to 30 mg) 30 minutes to 2 hours prior to the start of travel. Subsequent doses, if necessary during the journey, are repeated every 6 to 8 hours. If a dose is missed, a minimum interval of 8 hours must be maintained between the missed dose and the next scheduled intake.

Population-Specific Use

Children aged 5 to 12 years are prescribed approximately half the standard adult dose. The use of Cinnarizine is not recommended for children under the age of 5.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research has historically focused on Cinnaron (also known as cinnarizine) for its effects on symptoms associated with vertigo, balance disorders, and motion sickness. It is categorized as a calcium channel blocker and an antihistamine, properties which are thought to interfere with signal transmission within the inner ear and vestibular system.


Key Findings in Vestibular Disorders

Studies have investigated Cinnaron's impact, often in combination with other agents, for the management of vertigo originating from central or peripheral causes. Findings from an analysis of randomized trials reported:

  • Symptom Reduction: In one study involving patients with chronic vertigo, a fixed combination containing Cinnaron was associated with a reduction in dizziness and vertigo-related symptoms in more than 75% of participants after 60 days of therapy.
  • Comparative Studies: Research comparing the fixed combination of Cinnaron/dimenhydrinate against another common anti-vertigo drug (betahistine) in patients with peripheral vestibular vertigo reported differences in the overall reduction of the mean vertigo score (MVS) after four weeks of treatment. This combination therapy also received more favorable patient ratings regarding overall efficacy.

Other Areas of Research

Migraine: Cinnaron has been examined for its use as a preventive therapy for migraine, particularly in pediatric and adult populations. In a randomized, double-blind trial on childhood migraine, both Cinnaron and a comparator drug were found to be associated with improvements in headache characteristics.

Long-term Safety: Research acknowledges that long-term use of Cinnaron, particularly at higher doses, has been studied in relation to the development of movement disorders, such as drug-induced Parkinsonism, due to its action on dopamine receptors. This risk is a significant consideration for extended use.

Key Studies & References

  1. Cinnarizine and flunarizine in the prophylaxis of migraine in children: a randomized controlled trial

Frequently Asked Questions (FAQ)

Common questions about Cinnaron (FAQ)


Q: How quickly does Cinnaron start to work after the first dose?

A: According to pharmacokinetic studies, the active ingredient in Cinnaron reaches its highest concentration in the bloodstream within 1 to 4 hours after being taken orally. This time frame reflects when the medicine typically reaches its highest concentration in the body.


Q: Can Cinnaron be taken on an empty stomach?

A: Official administration information states that Cinnaron is typically taken after meals. This condition is noted on the label as being intended to help minimize the potential for gastric irritation or stomach upset.


Q: What is the mechanism of Cinnaron described in simple terms?

A: Cinnaron has a dual action, working as both a selective calcium channel blocker and an antihistamine. These properties help reduce signal transmission between the inner ear's balance mechanism and the brain, which works to influence pathways associated with vertigo symptoms.


Q: Does Cinnaron cause mood swings or anxiety?

A: Regulatory documents list depressed mood as a possible side effect of the medicine. Due to the way Cinnaron influences certain brain pathways, official guidance notes that caution is required for use in patients who have a history of depression.


Q: Does Cinnaron affect fertility in men or women?

A: Studies examining the effect on fertility in animals have found no evidence of adverse effects. Based on available human data, official information indicates that there is currently no evidence to suggest that the active ingredient reduces the ability to conceive.


Q: Can Cinnaron be used by breastfeeding mothers?

A: Official regulatory guidance restricts the use of Cinnaron in nursing mothers. This restriction is based on a lack of available data regarding how the active ingredient may be excreted into human breast milk.


Q: Can children take Cinnaron?

A: Official labeling includes specific age restrictions. Cinnaron is not recommended for children under the age of 5 years. For children aged 5 to 12 years, the drug is used under a modified administration schedule.


Q: Do I need to get blood tests while I am taking Cinnaron?

A: Routine blood testing is not generally mandated by official labeling for all patients. However, caution is advised for individuals with pre-existing hepatic (liver) or renal (kidney) insufficiency, as these conditions may influence how the body processes the drug.


Q: What is the usual period of treatment with Cinnaron?

A: The duration of Cinnaron use is determined by the condition being managed. For motion sickness prophylaxis, the medicine is taken short-term during travel. For balance disorders, treatment may extend over several months or be taken long-term for continuous management.


Q: What should I expect in the first week of starting Cinnaron?

A: Drowsiness, or somnolence, is listed as a very common side effect in official documents. This effect is noted as being particularly likely to appear during the initial phase of treatment.


Q: Is Cinnaron meant to cure the condition or just manage symptoms?

A: The official therapeutic indication describes Cinnaron as a treatment intended for the symptomatic management of balance and vestibular disorders. This means the medicine is used to manage and relieve symptoms rather than offering a cure for the underlying condition.


Q: Can Cinnaron be taken with over-the-counter pain relievers like ibuprofen?

A: Official drug information advises caution when Cinnaron is combined with any medication that acts as a central nervous system (CNS) depressant. Combining Cinnaron with certain pain relievers may potentially increase the sedative effects.


Q: Can I have caffeine while taking Cinnaron?

A: Regulatory guidance states that, apart from avoiding alcohol due to increased sedation risk, patients can generally maintain their normal eating and drinking habits while taking Cinnaron. There are no specific restrictions against caffeine consumption.


Q: Is Cinnaron approved in countries outside of the US?

A: Yes. The active ingredient in Cinnaron, cinnarizine, is approved and utilized under various brand names by regulatory agencies across many countries, including those in Europe, Australia, and parts of Asia.


Q: Is Cinnaron safe for people who have a history of heart problems?

A: Because Cinnaron has properties that can affect blood vessels, official documents require that individuals with coronary artery disease or hypotension (low blood pressure) be considered with caution.


Q: What happens if a person suddenly stops taking Cinnaron?

A: Official patient guidance indicates that if Cinnaron has been used for ongoing inner ear problems, discontinuing the treatment may lead to a return of the original symptoms, such as dizziness or vertigo.


Q: Are there any restrictions on driving or operating machinery while on Cinnaron?

A: Official product information contains a restriction against driving or operating machinery if the user experiences side effects such as drowsiness, dizziness, or impaired concentration. These effects are noted as being more likely when treatment is started.


Q: Why do people say Cinnaron is a 'last resort' drug?

A: Regulatory assessments in some regions indicate that Cinnaron is used for the short-term, symptomatic treatment of vertigo in adults. It may be utilized for patients who have not shown an adequate response to alternative, first-line treatments for the same condition.


Q: Is Cinnaron a brand-new drug or has it been around for a while?

A: Cinnarizine is not a new product; the active ingredient was first synthesized in 1955. This confirms its status as an established drug that has been used in various markets for many decades.


Q: Does Cinnaron contain any common allergens like gluten or lactose?

A: The official list of inactive ingredients, or excipients, confirms that Cinnaron tablets contain lactose monohydrate and sucrose. The presence of these components is noted in the patient safety information due to the risks associated with hereditary sugar intolerance.


Q: Can Cinnaron be crushed or split?

A: Patient guidance for the tablets mentions that they may be either swallowed whole with water, or alternatively, sucked or chewed. This provides flexibility for administration, especially for individuals who may have difficulty swallowing.


Q: What if I feel a little dizzy after starting Cinnaron?

A: Dizziness or drowsiness is a common side effect of Cinnaron, which official documentation notes is particularly frequent when first beginning treatment. If you experience these effects, official guidance states that the presence of these effects requires caution and that operating vehicles or heavy machinery is restricted.


How should Cinnaron be stored and disposed of?

How to Store and Dispose of Cinnaron?

Storage and disposal of Cinnaron (Cinnarizine) must adhere strictly to conditions documented in official regulatory labeling.


Storage Requirements

The medicine must be stored at a temperature not exceeding 30°C and must be protected from light.

Regulatory documents require the product to be kept out of the sight and reach of children and maintained in its original package. Do not use Cinnaron after the labeled expiry date, which often corresponds to a shelf life of 24 months.


Disposal Instructions

Unused or expired Cinnaron must not be thrown away via wastewater or household waste. Disposal should be managed in accordance with local requirements for pharmaceutical waste. Consult a pharmacist for guidance on proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinnaron found in:

A-Z Index: